Praiseldy Langi Sasongko

131 Using a scenario approach to assess for the current and future demand of immunoglobulins latest evidence in the biologics era. J Nephrol 2018; 31(3): 361-83. 44. Barut K, Sahin S, Adrovic A, Kasapcopur O. Diagnostic approach and current treatment options in childhood vasculitis. Türk Pediatri Arşivi 2015; 50(4): 194-205. 45. Lieberman L, Greinacher A, Murphy MF, et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol 2019. 46. Prefumo F, Fichera A, Fratelli N, Sartori E. Fetal anemia: Diagnosis and management. Best practice & research Clinical obstetrics & gynaecology 2019. 47. Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev 2010; 24 Suppl 1: S28-50. 48. Vultaggio A, Azzari C, Milito C, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig 2015; 35(3): 179-85. 49. Iro MA, Martin NG, Absoud M, Pollard AJ. Intravenous immunoglobulin for the treatment of childhood encephalitis. Cochrane Database Syst Rev 2017; 10: CD011367. 50. Gadian J, Kirk E, Holliday K, Lim M, Absoud M. Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders. Dev Med Child Neurol 2017; 59(2): 136-44. 51. Hopkins SE. Acute Flaccid Myelitis: Etiologic Challenges, Diagnostic and Management Considerations. Curr Treat Options Neurol 2017; 19(12): 48. 52. Nosadini M, Mohammad SS, Suppiej A, Sartori S, Dale RC. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome. Dev Med Child Neurol 2016; 58(11): 1180-92. 53. Rodriguez MM, Wagner-Weiner L. Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence. Pediatr Ann 2017; 46(1): e19-e24. 54. Florescu DF, Schaenman JM. Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical transplantation 2019; 33(9): e13527. 55. Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev 2010; 24 Suppl 1: S7-s27. 56. Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open 2018; 1(7): e184169. 57. Bhella S, Majhail NS, Betcher J, et al. Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group’s List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2018; 24(5): 909-13. 58. Brand A, De Angelis V, Vuk T, Garraud O, Lozano M, Politis D. Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2021; 28(1): 96-122. 59. Calizzani G, Vaglio S, Candura F, et al. The evolution of the regulatory framework for the plasma and plasmaderived medicinal products system in Italy. Blood transfusion = Trasfusione del sangue 2013; 11 Suppl 4: s6-12. 60. De Angelis V, Breda A. Plasma-derived medicinal products self-sufficiency from national plasma: to what extent? Blood transfusion = Trasfusione del sangue 2013; 11 Suppl 4: s132-7. 61. Farrugia A, Cassar J. Plasma-derived medicines: access and usage issues. Blood transfusion = Trasfusione del sangue 2012; 10(3): 273-8. 62. Farrugia A. Are we optimising outcomes in Australia’s framework for the supply of plasma-derived medicines? Med J Aust 2016; 205(7): 336. 63. Grazzini G, Ceccarelli A, Calteri D, Catalano L, Calizzani G, Cicchetti A. Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing. Blood transfusion = Trasfusione del sangue 2013; 11 Suppl 4: s138-47. 64. Kohn DB, Kuo CY. New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing. J Allergy Clin Immunol 2017; 139(3): 726-32.

RkJQdWJsaXNoZXIy MTk4NDMw